Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

A PROSPECTIVE EUROPEAN VALIDATION COHORT FOR STEREOTACTIC THERAPY OF RE-ENTRANT TACHYCARDIA

Project description

DE EN ES FR IT PL

Non-invasive treatment for ventricular tachycardia

Ventricular tachycardia (VT) is a life-threatening heart condition that can be treated with catheter ablation and medication. However, this treatment does not impede VT reoccurrence, and technical difficulties or patient refusal restrict its efficiency. While stereotactic arrhythmia radioablation (STAR) is an alternative non-invasive treatment option, there is a lack of studies that validate this method. The EU-funded STOPSTORM project will clinically validate STAR treatment, integrating all data in a validation cohort study and systematising pretreatment and follow-up to collect the data sets and statistical power necessary for safe and effective STAR. The project will also clarify protocols, define and model the best target region and dose, and determine patient groups and cardiopathies responding to STAR treatment.

Objective

Ventricular tachycardia (VT) is an unpredictable and potentially deadly condition and should be promptly treated with catheter ablation and medication, before irreversible and potentially fatal organ damage follows. Unfortunately, this combination of treatments does not prevent VT reoccurrence in 30-50% of VT patients and while they can undergo multiple invasive ablations, technical difficulties or refusal of the patient can lead to a lack of effective treatment options.

A promising novel, non-invasive treatment option for VT is stereotactic arrhythmia radioablation (STAR). Besides being non-invasive, STAR can also be used to reach locations that are inaccessible for catheter ablation, which may potentially improve effectiveness of overall VT treatment.

Small scale first in men/early phase trials have been performed for STAR, providing proof-of-concept for clinical safety and efficacy. However, patients with recurrent VT are not a homogenous group and each center deals with different inclusion criteria, imaging and/or target definition. Many questions remain and the available studies lack the power to clinically validate the approach and prepare for late stage phase III trials.

The STOPSTORM consortium sets out to consolidate all current and future European efforts to clinically validate STAR treatment by merging all data in a validation cohort study, standardising pre-treatment and follow-up, in order to collect the data sets and statistical power needed to unanimously establish clinical safety, efficacy and benefit for STAR.

The STOPSTORM consortium also sets out to refine protocols and guidelines, determine volumes of interest, define and model the optimal target region and target dose, also in relation to surrounding healthy tissues (i.e. organs at risk) and determine which patient population and underlying cardiopathies respond best to STAR. By doing so the STOPSTORM consortium paves the way to consensus and future late stage clinical trials for STAR.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2020-Two-Stage-RTD

Funding Scheme

RIA - Research and Innovation action

Coordinator

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Net EU contribution
€ 644 744,16
Address
OLSHAUSENSTRASSE 40
24118 Kiel
Germany

See on map
Region
Schleswig-Holstein Schleswig-Holstein Kiel, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 699 744,16

Participants (30)

Share this page

Download

Last update: 30 September 2024

My Booklet

Permalink: https://cordis.europa.eu/project/id/945119

European Union, 2024